Cambridge, UK – 26 May 2022: ENHANC3D GENOMICS (“Enhanc3D”), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation’s Immunology Innovations QuickFire Challenge.
Lead therapeutic candidate has the potential to treat Stress Urinary Incontinence Raising … Continue reading “Versameb to Present during World Continence Week 2022”
Nordic Bioscience, a growing biomarker company, today announced the strengthening of its … Continue reading “Nordic Bioscience and Roche Diagnostics Strengthen Collaboration for Development of Biomarkers for Chronic Diseases”
Keele, UK, 15 June 2022 – Biocomposites, an international medical devices company that … Continue reading “Biocomposites appoints Group Chief Financial Officer and New UK General Manager”
Top-line data expected from ENHANCE-2 in Q3 2022 and ENHANCE-1 around the … Continue reading “Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD”
PKA pension fund lead investment, alongside The Danish Growth Fund and Eir … Continue reading “Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)”
Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc., a market leading … Continue reading “ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study”
Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined … Continue reading “Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers”
Willington, UK, 7 June 2022 – Bionical Solutions, a leading provider of technology … Continue reading “Bionical Solutions Bolsters Clinical Services Team”
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) — Verona Pharma … Continue reading “Verona Pharma to Host KOL Event on June 16, 2022”
Brighton, United Kingdom – 27 May 2022 – Destiny Pharma plc (AIM: DEST), a … Continue reading “Destiny Pharma plc – Result of Annual General Meeting and Strategy Update”
Brighton, United Kingdom – 26 May 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage … Continue reading “Destiny Pharma appoints three Non-Executive Directors”
Los Angeles, USA and Yantai, China – May 24th, 2022 – ImaginAb, Inc., … Continue reading “ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community”
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative … Continue reading “Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland”
Deal value includes upfront payment of US$100 million with F2G eligible for … Continue reading “Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia”
Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica drug delivery … Continue reading “DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology”
NEW YORK & PARIS (May 16, 2022) – Apollo (NYSE: APO) and Sofinnova Partners (“Sofinnova”), a … Continue reading “Sofinnova Partners and Apollo form strategic partnership in life sciences”
Shionogi to conduct clinical trials, subsequent registration, and commercialization of olorofim for … Continue reading “Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia”
Brighton, United Kingdom – 12 May 2022 – Destiny Pharma (AIM: DEST), a … Continue reading “Destiny Pharma – World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
